Breast Cancer

Showing NaN - NaN of 215

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Breast Cancer Trial in Worldwide (Dato-DXd, Durvalumab, Pembrolizumab)

Not yet recruiting
  • Breast Cancer
  • Jonesboro, Arkansas
  • +142 more
Oct 31, 2023

Breast Cancer Trial in Worldwide (GDC-9545, Palbociclib, LHRH Agonist)

Active, not recruiting
  • Breast Cancer
  • Aurora, Colorado
  • +23 more
Jan 30, 2023

Breast Cancer Trial in United States (ARV-471, ARV-471 in combination with palbociclib (IBRANCEĀ®))

Recruiting
  • Breast Cancer
  • ARV-471
  • ARV-471 in combination with palbociclib (IBRANCEĀ®)
  • Palo Alto, California
  • +16 more
Jan 30, 2023

Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer Trial in New York, Fairfax, Spokane (XMT-1660)

Recruiting
  • Triple Negative Breast Cancer
  • +5 more
  • Orange, California
  • +6 more
Jan 23, 2023

Breast Cancer Trial in United States (Positron emission tomography (PET), Trastuzumab, Pertuzumab)

Active, not recruiting
  • Breast Cancer
  • Positron emission tomography (PET)
  • +2 more
  • Birmingham, Alabama
  • +9 more
Jan 20, 2023

Breast Cancer Trial in Worldwide (Dato-DXd, Paclitaxel, Nab-paclitaxel)

Recruiting
  • Breast Cancer
  • Duarte, California
  • +260 more
Jan 19, 2023

Breast Cancer Trial in Worldwide (Dato-DXd, Durvalumab, Capecitabine)

Recruiting
  • Breast Cancer
  • Gilbert, Arizona
  • +165 more
Jan 17, 2023

Breast Tumors, Breast Cancer, HER2-positive Early Breast Cancer Trial in Worldwide (Trastuzumab Deruxtecan, Paclitaxel,

Recruiting
  • Breast Neoplasms
  • +2 more
  • Trastuzumab Deruxtecan
  • +5 more
  • Springdale, Arkansas
  • +203 more
Jan 13, 2023

Breast Cancer, Solid Tumor Trial in Worldwide (Inavolisib, Fulvestrant, Letrozole)

Recruiting
  • Breast Cancer
  • Solid Tumor
  • Boston, Massachusetts
  • +12 more
Jan 10, 2023

Breast Cancer Trial in Worldwide (Atezolizumab, Trastuzumab Emtansine, Placebo)

Recruiting
  • Breast Cancer
  • Alabaster, Alabama
  • +305 more
Jan 10, 2023

Multiparametric MRI asNon-Invasive Biomarker of Tumor

Recruiting
  • Breast Cancer
  • Triple-negative Breast Cancer
  • Tempus assay
  • +2 more
  • Nashville, Tennessee
    Vanderbilt University Medical Center
Jan 10, 2023

Breast Cancer Trial in Worldwide (Inavolisib, Placebo, Palbociclib)

Recruiting
  • Breast Cancer
  • Tucson, Arizona
  • +228 more
Jan 10, 2023

Breast Cancer Trial in Sarasota, Nashville (AC699)

Recruiting
  • Breast Cancer
  • Sarasota, Florida
  • +1 more
Jan 3, 2023

Breast Cancer, Breast Tumors, Colon Cancer Trial in United States (AZD6244, Dacarbazine, Erlotinib)

Active, not recruiting
  • Breast Cancer
  • +7 more
  • Detroit, Michigan
  • +3 more
Dec 22, 2022

Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Tumor Trial in Worldwide (G1T48, Palbociclib)

Completed
  • Carcinoma, Ductal, Breast
  • +6 more
  • Beverly Hills, California
  • +14 more
Dec 14, 2022

Breast Cancer Trial in Denver, Sarasota, Nashville (AC682)

Recruiting
  • Breast Cancer
  • Denver, Colorado
  • +4 more
Dec 12, 2022

HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer Trial in United States (Pertuzumab+TRASTUZUMAB,

Recruiting
  • HER2-positive Breast Cancer
  • +5 more
  • Pertuzumab+TRASTUZUMAB
  • ADJUVANT ENDOCRINE THERAPY
  • Stamford, Connecticut
  • +21 more
Dec 12, 2022

Breast Cancer Trial in Worldwide (Dato-DXd, Capecitabine, Gemcitabine)

Active, not recruiting
  • Breast Cancer
  • Duarte, California
  • +172 more
Dec 1, 2022

Breast Cancer Trial in Greece, Israel, United States (MammaPrint, BluePrint, and Full-Genome Testing)

Recruiting
  • Breast Cancer
  • MammaPrint, BluePrint, and Full-Genome Testing
  • Birmingham, Alabama
  • +117 more
Dec 1, 2022

Breast Tumors, Breast Cancer, Breast Tumors Trial in United States (Standard Therapy, AMG 386 with or without Trastuzumab, AMG

Recruiting
  • Breast Neoplasms
  • +10 more
  • Standard Therapy
  • +32 more
  • Birmingham, Alabama
  • +35 more
Nov 17, 2022

Melanoma, Prostate Cancer, Ovarian Cancer Trial in United States (Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or

Active, not recruiting
  • Melanoma
  • +8 more
  • Los Angeles, California
  • +9 more
Nov 15, 2022

Validation for Early Cancer Detection and Minimal Residual

Recruiting
  • Brain Cancer
  • +19 more
    • Duarte, California
    • +6 more
    Nov 10, 2022